PDGFA and Miyoshi myopathy: Specifically, the MM ECs were predicted to produce higher levels of PDGFA, LAMA4, JAM3, COL4A1, CD46, and ANGPTL4, which may have interacted with the receptors on the mesenchymal stem cells (MSCs), malignant plasma cells, and immune cells.